Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Food as a Bariatric Drug

Author(s): Richard L. Shriner

Volume 17, Issue 12, 2011

Page: [1198 - 1208] Pages: 11

DOI: 10.2174/138161211795656710

Price: $65


as obesity, type 2 diabetes (T2DM) and the metabolic syndrome sweep across the research and the clinical landscape of medical care, effective pharmacologic remedies for the treatment of obesity have become imperative. The complexities of nutrient impact on neurotransmitter and endocrine modulating chemistry have become increasingly better characterized as have the basic neurochemical pathways that mediate their effects. Food addiction has emerged as an important phenomenon that may help to explain and improve our capabilities of rendering bench lab research into impactful clinical intervention. Against this challenging backdrop of current research and study we introduce the notion that food may, itself, represent a type of drug. In this review of food as a drug, we outline some of the emerging science that argues how proteins, carbohydrates and fats operating on three basic levels of organismic functioning may constitute the most powerful drugs we have available to effectuate weight loss or weight gain over time. In addition, certain foods may not only be more addictive than others, but may actually have a direct effect on pro-inflammatory mediators that determine both metabolic dysfunction as well as overall neuropsychiatric function and well-being.

Keywords: Food addiction, Obesity, Overeating, Type 2 Diabetes (T2DM), High fructose corn syrup, Weight loss therapy, Metabolic resiliency, Cognitive therapy, Medical social networking, Group fellowship, metformin, allostatic, neurocognitive, bariac, D-Fenfluramine, rimonabant, anorexigenic, resilient, thermogenic, pharmacopeia, melanocortin, adipocyte, thiazolidinediones, opioids

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy